 - Parts A: Histologically or cytologically documented solid tumor malignancy or non-Hodgkins lymphoma Part B: renal cell carcinoma, Part C: non-small cell lung carcinoma with clinical evidence of advanced andor metastatic disease, which is refractory to established forms of therapy or for which no effective therapy exists, or for which sorafenib alone would be considered by the investigator as an appropriate therapy; patients who have refused available standard therapies would also be deemed eligible 